Rome, 15 Nov. (Adnkronos Health) – Women with breast cancer and their caregivers still know little about precision oncology, an approach that allows identifying the molecular characteristics of the tumor and choosing more targeted treatments. Only 32% of respondents know that liquid biopsy is a blood test that allows identifying the presence of circulating tumor cells or molecules. 43% are unaware of targeted cancer therapies, and only 24% know what Molecular Tumor Boards are – multidisciplinary groups of specialists who evaluate cases and help identify the most appropriate therapies. For 95%, however, the functioning of Next-generation sequencing (Ngs) technology, used to analyze the tumor’s genetic material, is still poorly understood.
Despite these gaps, eight out of ten people consider it necessary and important to have greater dialogue with doctors to choose the most suitable treatments. The data emerged from a survey promoted in recent months by the Aiom Foundation and conducted, with the collaboration of patient associations, on 752 people including patients and caregivers. The results were presented today, on the last day of the XXVIII national congress of the Italian Association of Medical Oncology (Aiom). The survey is part of the “Breast cancer and precision medicine” campaign, which includes webinars, an informative brochure, and social media activities. The initiative, made possible by an unrestricted sponsorship from Menarini Stemline, aims to delve deeper into these topics and raise awareness of the importance of precision oncology in improving care pathways.
“Precision oncology today represents one of the most significant advances in the treatment of many neoplasms – underlines Francesco Perrone, president of the Aiom Foundation -. Through increasingly accurate diagnostic-molecular tests, it is possible to thoroughly characterize the disease, identify specific biological alterations, and select the most appropriate treatments. All this becomes even more relevant when we have to deal with high-incidence neoplasms such as breast carcinoma. With over 53,000 new cases per year in our country alone, it is one of the most frequent forms of cancer, with numbers destined to grow. However, the positive results, induced by innovation and continuous scientific research, are not always truly known. This is what emerges from the survey, which shows a poor understanding of the innovative tests introduced in recent years in clinical practice. There is certainly room to improve information for patients.” Also according to the survey, 29% of patients were prescribed a molecular test, but almost half encountered difficulties in performing it. In particular, 24% had to go to another healthcare facility, while 23% complained of excessively long waiting times.